Peptide therapeutics and methods for using same

• US 10,293,020 B2
• Filed: 06/24/2014
• Issued: 05/21/2019
• Est. Priority Date: 06/27/2013
• Status: Active Grant

• Current Assignee: Stealth BioTherapeutics, Inc. (Morningside Group Ltd.)
• Original Assignee: Stealth BioTherapeutics Corp. (Morningside Group Ltd.)
• Inventors: Wilson, D. Travis
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US14/899,439
• Publication Number:
  US 20160151446A1
• Time in Patent Office: 1,792 Days
• Field of Search: None
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/095 Oxytocins; Vasopressins; Related peptides
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/13 Cyclosporins

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogs of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH₂).

Claims

1. A composition comprising the mitochondria penetrating peptide (MPP) Cha-Arg-Cha-Lys-NH₂ alone or in combination with one or more aromatic-cationic peptides selected from the group consisting of:

2′

6′

-Dmp-D-Arg-2′

6′

-Dmt-Lys-NH₂;

2′

,6′

-Dmt-D-Arg-Phe-Lys-NH₂;

2′

6′

-Dmp-D-Arg-Phe-Lys-NH₂;

2′

6′

-Dmt-D-Arg-PheOrn-NH₂;

2′

6′

-Dmt-D-Arg-Phe-Ahp(2-aminoheptanoicacid)-NH₂;

2′

6′

-Dmt-D-Arg-Phe-Lys-NH₂;

2′

6′

-Dmt-D-Cit-PheLys-NH₂;

Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe;

Arg-D-Dmt-Arg-NH₂;

Arg-D-Dmt-Lys-NH₂;

Arg-D-Dmt-NH₂;

Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly;

Arg-D-Tyr-Arg-NH₂;

Arg-D-Tyr-Lys-NH₂;

Arg-D-Tyr-NH₂;

Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe;

Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg-D-Gly-Lys-NH₂;

D-Arg-2′

6′

-Dmt-Lys-Phe-NH₂;

D-Arg-Arg-Dmt-Phe-NH₂;

D-Arg-Arg-Tyr-Phe-NH₂;

D-Arg-Cha-Lys-Cha-NH₂;

D-Arg-Cha-Lys-NH₂;

D-Arg-D-Dmt-NH₂;

D-Arg-Dmt-D-Lys-Phe-NH₂;

D-Arg-Dmt-Lys-Dmt-Lys-Met-NH₂;

D-Arg-Dmt-Lys-Dmt-Lys-Trp-NH₂;

D-Arg-Dmt-Lys-D-Phe-NH₂;

D-Arg-Dmt-Lys-NH₂;

D-Arg-Dmt-Lys-Phe-Lys-Met-NH₂;

D-Arg-Dmt-Lys-Phe-Lys-Trp-NH₂;

D-Arg-Dmt-Lys-Phe-Met-NH₂;

D-Arg-Dmt-Lys-Trp-NH₂;

D-Arg-Dmt-NH₂;

D-Arg-Dmt-Phe-NH₂;

D-Arg-D-Tyr-D-Lys-D-Phe-NH₂;

D-Arg-D-Tyr-Lys-Phe-NH₂;

D-Arg-D-Tyr-NH₂;

D-Arg-Phe-Lys-NH₂;

D-Arg-Trp-Lys-NH₂;

D-Arg-Trp-Lys-Trp-NH₂;

D-Arg-Tyr-D-Lys-Phe-NH₂;

D-Arg-Tyr-Lys-D-Phe-NH₂;

D-Arg-Tyr-Lys-NH₂;

D-Arg-Tyr-Lys-Phe-NH₂;

D-Arg-Tyr-NH₂;

D-Arg-Tyr-Phe-NH₂;

D-Dmt-Arg-NH₂;

D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH₂;

D-His-Glu-Lys-Tyr-D-Phe-Arg;

D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-Asp-D-His-D-Lys-Arg-Trp-NH₂;

Dmt-D-Arg-NH₂;

Dmt-D-Phe-Arg-Lys-NH₂;

Dmt-Lys-D-Phe-NH₂;

Dmt-Lys-NH₂;

Dmt-Lys-Phe-NH₂;

D-Nle-Cha-Ahe-Cha-NH₂;

D-Nle-Dmt-Ahe-Phe-NH₂;

D-Phe-D-Arg-D-Phe-D-Lys-NH₂;

D-Tyr-Arg-NH₂;

D-Tyr-Trp-Lys-NH₂;

Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH₂;

Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp;

Gly-D-Phe-Lys-His-D-Arg-Tyr-NH₂;

H-D-Arg(Nα

Me)-Dmt(NMe)-Lys(Nα

Me)-Phe(NMe)-NH₂;

H-D-Arg-Dmt-Lys(Nα

Me)-Phe(NMe)-NH₂;

H-D-Arg-Dmt-Lys(Nα

Me)-Phe-NH₂;

H-D-Arg-Dmt-Lys-Phe(NMe)-NH₂;

H-D-Arg-Dmt-Lys-Phe-Sar-Gly-Cys-NH₂;

H-D-Arg-Dmt-LysΨ

[CH2-NH]Phe-NH₂;

H-D-Arg-Dmt-Ψ

[CH2-NH]Lys-Phe-NH₂;

H-D-Arg-Dmt-Ψ

[CH2-NH]Lys-Ψ

[CH2-NH]Phe-NH₂;

H-D-Arg-Ψ

[CH2-NH]Dmt-Lys-Phe-NH₂;

His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH₂;

Lys-D-Arg-Tyr-NH₂;

Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH₂;

Lys-Dmt-D-Arg-NH₂;

Lys-D-Phe-Arg-Dmt-NH₂;

Lys-D-Phe-Arg-Tyr-NH₂;

Lys-Phe-NH₂;

Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH₂;

Met-Tyr-D-Arg-Phe-Arg-NH₂;

Met-Tyr-D-Lys-Phe-Arg;

Phe-Arg-D-His-Asp;

Phe-D-Arg-2′

6′

-Dmt-Lys-NH₂;

Phe-D-Arg-D-Phe-Lys-NH₂;

Phe-D-Arg-His;

Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His;

Phe-D-Arg-Phe-D-Lys-NH₂;

Phe-D-Arg-Phe-Lys-NH₂;

Phe-D-Dmt-Arg-Lys-NH₂;

Phe-D-Tyr-Arg-Lys-NH₂;

Phe-Lys-Dmt-NH₂;

Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH₂;

Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr;

Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys;

Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH₂;

Trp-D-Lys-Tyr-Arg-NH₂;

Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys;

Tyr-Asp-D-Lys-Tyr-Phe-D-Lys-D-Arg-Phe-Pro-D-Tyr-His-Lys;

Tyr-D-Arg-NH₂;

Tyr-D-Arg-Phe-Lys-Glu-NH₂;

Tyr-D-Arg-Phe-Lys-NH₂;

Tyr-D-His-Phe-D-Arg-Asp-Lys-D-Arg-His-Trp-D-His-Phe;

Tyr-D-Phe-Arg-Lys-NH₂;

Tyr-His-D-Gly-Met; and

Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH₂,

and further comprising one or more additional active agents selected from the group consisting of cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.

2. The composition of claim 1, wherein the MPP further comprises a modification selected from the group consisting of inclusion of one or more D-amino acids, inclusion of one or more sites of N-methylation, and inclusion of one or more reduced amide bonds (Ψ

[CH2-NH]).

3. The composition of claim 1, further comprising at least one pharmaceutically acceptable pH-lowering agent and at least one absorption enhancer comprising an absorbable or biodegradable surface active agent selected from the group consisting of an acylcarnitine, a phospholipid, a bile acid, and a sucrose ester.

4. The composition of claim 3, wherein the pH-lowering agent is selected from the group consisting of citric acid, tartaric acid, and an acid salt of an amino acid.

5. The composition of claim 3, wherein the composition comprises a lamination having a first layer comprising the at least one pharmaceutically acceptable pH-lowering agent and a second layer comprising the MPP alone or in combination with one or more aromatic-cationic peptides and further comprising the at least one absorption enhancer, wherein the first and second layers are united with each other, but wherein the layers prevent interaction between the pH-lowering agent and the peptide(s).